利和兴：2025年前三季度净利润约-6588万元

Group 1 - The core point of the article highlights that Lihexing (SZ 301013) reported a revenue of approximately 327 million yuan for the first three quarters of 2023, representing a year-on-year decrease of 8.85% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 65.88 million yuan, with basic earnings per share reflecting a loss of 0.28 yuan [1] - As of the report date, Lihexing's market capitalization stands at 6.7 billion yuan [1] Group 2 - The article also mentions that the Chinese innovative drug sector has sold overseas authorizations worth 80 billion US dollars this year, indicating a robust performance in the biopharmaceutical secondary market [1] - A dialogue with Lu Gang, a partner at Chuangdongfang Investment, points out the contrast between the hot secondary market and the cooling fundraising environment in the primary market for the biopharmaceutical sector [1]